- Home
- AUST vs COCP Comparison
AUST vs COCP Comparison
Compare AUST & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AUST | COCP |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 15.3M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | AUST | COCP |
|---|---|---|
| Price | $1.47 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 272.4K | 36.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $0.86 |
| 52 Week High | $3.92 | $2.19 |
Technical Indicators
Market Signals| Indicator | AUST | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 52.69 |
| Support Level | $1.20 | $1.00 |
| Resistance Level | $1.45 | $1.11 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 7.50 | 42.26 |
Price Performance
Historical ComparisonAbout AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).